[The antifibrillatory properties of bonnecor]. / Protivofibrilliatornye svoistva bonnekora.

The preventive and therapeutic effects of bonnecor were shown in the experiments on awake and anesthetized rats under conditions of acute myocardial ischemia. It was concluded that the relieving influence of bonnecor on the course of acute myocardial ischemia was related to its antifibrillatory and antiarrhythmic properties.

[Anti-arrhythmia and antifibrillatory properties of dibenzazepine derivatives]. / Antiaritmicheskie i antifibrilliatornye svoistva proizvodnykh dibenzazepina.

Antiarrhythmic and antifibrillation properties of bonnecor, a derivative of dibenzepin, were studied in comparison with ethmozine, quinidine and novocainamide, using various experimental arrhythmia models. Bonnecor activity was somewhat smaller than that of ethmozine, and much greater than that of quinidine and novocainamide in the mixed atrioventricular arrhythmia model simulated in aconitin-treated rats and the ventricular arrhythmia model simulated by two-degree coronary occlusion in dogs. Intravenous 1 mg/kg and oral 6 mg/kg bonnecor doses prevented ventricular fibrillation caused by acute coronary occlusion in rats, while ethmozine showed no such effect.

[Comparative study of the activity of anti-arrhythmia agents in calcium chloride-induced arrhythmia in mice]. / Sravnitel'noe izuchenie aktivnosti antiaritmicheskikh sredstv pri khloridkal'tsievoi aritmii u myshei.

Calcium chloride (280 mg/kg intravenously) provokes arrhythmia, heart fibrillation and death of mice. Pretreatment with isoptin, etmozine, lidocaine, trimecaine, quinidine and novocainamide prevents rhythm disorders and animals' death. Isoptin, etmozine, lidocaine and trimecaine have been found the most effective. Atropine does not produce any protective action. The simplicity and availability of the method described enables one to apply it as a model for search of new antiarrhythmic drugs.